Glenmark Divests API Company, Setting Out On Distinct Journeys
Executive Summary
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”
You may also be interested in...
Glenmark Lays Out US Flovent Plans, Discusses Growing Debt Pile
India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.
India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
India Q2 2023 Deal Trends, What May Be In Store
India’s healthcare and life sciences segment saw deals worth over $3bn in Q2 2023 turbocharged by private equity activity in the hospitals space and smaller biopharma acquisitions. Watch the APIs and brands space for heightened M&A action, say experts.